CN103732236B - 用于生产痘苗病毒的方法和组合物 - Google Patents
用于生产痘苗病毒的方法和组合物 Download PDFInfo
- Publication number
- CN103732236B CN103732236B CN201280038029.8A CN201280038029A CN103732236B CN 103732236 B CN103732236 B CN 103732236B CN 201280038029 A CN201280038029 A CN 201280038029A CN 103732236 B CN103732236 B CN 103732236B
- Authority
- CN
- China
- Prior art keywords
- vaccinia virus
- culture
- virus
- cell
- hela cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24151—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
培养基的名称 | 供应商 |
ExCell HeLa SFM | SAFC |
ExCell 293 SFM | SAFC |
OPTIPRO SFM | Invitrogen |
UltraCulture | Cambrex |
CHO-S-SFM II | Invitrogen |
293 SFM II | Invitrogen |
VP-SFM | Invitrogen |
IS-293-V | Irvine Scientific |
BD Nu Serum补充物 | BD Biosciences |
特征 | 方法 |
传染性滴度 | 噬斑测定 |
效能:细胞毒性 | 在U2OS细胞上的ED50 |
基因组滴度 | E9L的qPCR |
总DNA | pico green |
宿主细胞DNA量 | qDNA-PCR |
总蛋白(ug/mL) | BCA |
宿主细胞蛋白(总体) | ELISA(Cygnus) |
Claims (20)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161515724P | 2011-08-05 | 2011-08-05 | |
US61/515,724 | 2011-08-05 | ||
PCT/US2012/049550 WO2013022764A1 (en) | 2011-08-05 | 2012-08-03 | Methods and compositions for production of vaccina virus |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103732236A CN103732236A (zh) | 2014-04-16 |
CN103732236B true CN103732236B (zh) | 2017-09-15 |
Family
ID=46650950
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280038029.8A Active CN103732236B (zh) | 2011-08-05 | 2012-08-03 | 用于生产痘苗病毒的方法和组合物 |
Country Status (12)
Country | Link |
---|---|
US (3) | US9719105B2 (zh) |
EP (1) | EP2739293B1 (zh) |
JP (1) | JP6243333B2 (zh) |
KR (1) | KR102022952B1 (zh) |
CN (1) | CN103732236B (zh) |
AU (1) | AU2012294606B2 (zh) |
BR (1) | BR112014000787B1 (zh) |
CA (1) | CA2841831C (zh) |
DK (1) | DK2739293T3 (zh) |
ES (1) | ES2813413T3 (zh) |
PL (1) | PL2739293T3 (zh) |
WO (1) | WO2013022764A1 (zh) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2954841A1 (en) | 2014-07-16 | 2016-01-21 | Transgene Sa | Oncolytic virus for expression of immune checkpoint modulators |
WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
ES2795010T3 (es) * | 2015-06-19 | 2020-11-20 | Sillajen Inc | Composiciones y métodos para la embolización viral |
CN106676071B (zh) * | 2015-11-06 | 2019-07-19 | 天士力创世杰(天津)生物制药有限公司 | HeLa-F细胞及其用途 |
EP3452081A1 (en) | 2016-05-04 | 2019-03-13 | Transgene SA | Combination therapy with cpg tlr9 ligand |
US20190328869A1 (en) | 2016-10-10 | 2019-10-31 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
KR20190097240A (ko) | 2016-12-28 | 2019-08-20 | 트랜스진 에스.에이. | 종양용해성 바이러스 및 치료 분자 |
JP2020517737A (ja) | 2017-04-21 | 2020-06-18 | シルラゼン, インコーポレイテッド | 腫瘍溶解性ワクシニアウイルスおよびチェックポイント阻害剤の併用療法 |
JP7334124B2 (ja) | 2017-06-21 | 2023-08-28 | トランジェーヌ | 個別化ワクチン |
WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
EP3617230A1 (en) | 2018-09-03 | 2020-03-04 | BioInvent International AB | Novel antibodies and nucleotide sequences, and uses thereof |
CN113330111A (zh) * | 2018-11-21 | 2021-08-31 | 西方溶瘤细胞有限公司 | 病毒的制造 |
CA3124773A1 (en) | 2018-12-28 | 2020-07-02 | Transgene | M2-defective poxvirus |
KR102228267B1 (ko) | 2019-01-25 | 2021-03-17 | 바이로큐어 주식회사 | Bhk-21 세포를 이용한 바이러스 생산방법 |
EP3842065A1 (en) | 2019-12-23 | 2021-06-30 | Transgene | Process for designing a recombinant poxvirus for a therapeutic vaccine |
CA3183701A1 (en) | 2020-06-22 | 2021-12-30 | Sung Jin Kim | Method for large scale-production of vaccinia virus using suspension cells |
WO2022013221A1 (en) | 2020-07-13 | 2022-01-20 | Transgene | Treatment of immune depression |
WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
EP4329786A1 (en) | 2021-04-30 | 2024-03-06 | KaliVir Immunotherapeutics, Inc. | Oncolytic viruses for modified mhc expression |
WO2023025899A2 (en) | 2021-08-26 | 2023-03-02 | Transgene | Delivery system for targeting genes of the interferon pathway |
TW202321458A (zh) | 2021-09-22 | 2023-06-01 | 瑞典商生物創新國際公司 | 新穎抗體組合及其用途 |
GB2614309A (en) | 2021-12-24 | 2023-07-05 | Stratosvir Ltd | Improved vaccinia virus vectors |
CN114395538A (zh) * | 2022-01-19 | 2022-04-26 | 和元生物技术(上海)股份有限公司 | 一种促进重组病毒载体向细胞外分泌的方法 |
WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
WO2024003353A1 (en) | 2022-07-01 | 2024-01-04 | Transgene | Fusion protein comprising a surfactant-protein-d and a member of the tnfsf |
WO2024038175A1 (en) | 2022-08-18 | 2024-02-22 | Transgene | Chimeric poxviruses |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6267965B1 (en) * | 1981-12-24 | 2001-07-31 | Virogenetics Corporation | Recombinant poxvirus—cytomegalovirus compositions and uses |
WO2008113078A1 (en) * | 2007-03-15 | 2008-09-18 | Jennerex, Inc. | Oncolytic vaccinia virus cancer therapy |
EP2085092A1 (en) * | 2008-01-29 | 2009-08-05 | Bayer Schering Pharma Aktiengesellschaft | Attenuated oncolytic paramyxoviruses encoding avian cytokines |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA68327C2 (en) * | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
NZ524661A (en) * | 2000-11-23 | 2005-03-24 | Bavarian Nordic As | Modified vaccinia ankara virus variant |
US7445924B2 (en) * | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
EP2044948B1 (en) | 2002-08-12 | 2013-10-30 | Jennerex Biotherapeutics ULC | Vaccinia viruses for use in treating cancer |
DK1869171T4 (en) * | 2005-04-11 | 2016-01-18 | Crucell Holland Bv | Virus cleaning using ultrafiltration |
CA2621982C (en) * | 2005-09-07 | 2017-11-28 | Jennerex Biotherapeutics Ulc | Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses |
AU2007282612B2 (en) * | 2006-08-07 | 2012-08-23 | Japan As Represented By Director-General Of National Institute Of Infectious Diseases | Method for production of live smallpox vaccine |
US8003364B2 (en) * | 2007-05-14 | 2011-08-23 | Bavarian Nordic A/S | Purification of vaccinia viruses using hydrophobic interaction chromatography |
WO2009048769A2 (en) * | 2007-10-10 | 2009-04-16 | Kirin Pharma Kabushiki Kaisha | Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same |
JP2013500717A (ja) | 2009-07-28 | 2013-01-10 | コーニング インコーポレイテッド | 細胞を培養するための合成マイクロキャリア |
ES2848650T3 (es) * | 2009-09-14 | 2021-08-11 | Sillajen Biotherapeutics Inc | Terapia combinada contra el cáncer con virus vaccinia oncolítico |
-
2012
- 2012-08-03 BR BR112014000787-0A patent/BR112014000787B1/pt active IP Right Grant
- 2012-08-03 US US14/236,982 patent/US9719105B2/en active Active
- 2012-08-03 KR KR1020147005901A patent/KR102022952B1/ko active IP Right Grant
- 2012-08-03 WO PCT/US2012/049550 patent/WO2013022764A1/en active Application Filing
- 2012-08-03 PL PL12746243T patent/PL2739293T3/pl unknown
- 2012-08-03 EP EP12746243.0A patent/EP2739293B1/en active Active
- 2012-08-03 CN CN201280038029.8A patent/CN103732236B/zh active Active
- 2012-08-03 ES ES12746243T patent/ES2813413T3/es active Active
- 2012-08-03 CA CA2841831A patent/CA2841831C/en active Active
- 2012-08-03 DK DK12746243.0T patent/DK2739293T3/da active
- 2012-08-03 AU AU2012294606A patent/AU2012294606B2/en active Active
- 2012-08-03 JP JP2014524110A patent/JP6243333B2/ja active Active
-
2017
- 2017-06-27 US US15/634,765 patent/US10202581B2/en active Active
-
2019
- 2019-02-07 US US16/270,585 patent/US10767166B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6267965B1 (en) * | 1981-12-24 | 2001-07-31 | Virogenetics Corporation | Recombinant poxvirus—cytomegalovirus compositions and uses |
WO2008113078A1 (en) * | 2007-03-15 | 2008-09-18 | Jennerex, Inc. | Oncolytic vaccinia virus cancer therapy |
EP2085092A1 (en) * | 2008-01-29 | 2009-08-05 | Bayer Schering Pharma Aktiengesellschaft | Attenuated oncolytic paramyxoviruses encoding avian cytokines |
Non-Patent Citations (4)
Title |
---|
A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma;A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Tar;《Molecular Therapy》;20110719;第19卷(第10期);第1913-1922 * |
Comparative Proteomics of Human Monkeypox and Vaccinia Intracellular Mature and Extracellular Enveloped Virions;Nathan P. Manes等;《Journal of proteome research》;20080301;第7卷(第3期);第960-968页 * |
Exploring Vaccinia Virus as a Tool for Large-Scale Recombinant Protein Expression;Nicole A. Bleckwenn等;《Biotechnol. Prog.》;20031231;第19卷(第1期);第130-136页 * |
Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSF;J. H. Kim等;《Molecular therapy》;20060812;第14卷(第3期);第361-370页 * |
Also Published As
Publication number | Publication date |
---|---|
DK2739293T3 (da) | 2020-08-24 |
PL2739293T3 (pl) | 2020-11-16 |
CA2841831C (en) | 2019-12-31 |
ES2813413T3 (es) | 2021-03-23 |
WO2013022764A1 (en) | 2013-02-14 |
JP6243333B2 (ja) | 2017-12-06 |
JP2014521353A (ja) | 2014-08-28 |
EP2739293A1 (en) | 2014-06-11 |
AU2012294606A1 (en) | 2014-01-23 |
KR20140058601A (ko) | 2014-05-14 |
US20140162342A1 (en) | 2014-06-12 |
US10202581B2 (en) | 2019-02-12 |
AU2012294606B2 (en) | 2016-10-06 |
US20170298324A1 (en) | 2017-10-19 |
US10767166B2 (en) | 2020-09-08 |
US20190169578A1 (en) | 2019-06-06 |
BR112014000787A2 (pt) | 2017-07-11 |
KR102022952B1 (ko) | 2019-09-20 |
EP2739293B1 (en) | 2020-06-10 |
US9719105B2 (en) | 2017-08-01 |
BR112014000787B1 (pt) | 2021-04-13 |
CA2841831A1 (en) | 2013-02-14 |
CN103732236A (zh) | 2014-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103732236B (zh) | 用于生产痘苗病毒的方法和组合物 | |
RU2489486C2 (ru) | Процесс получения поксвирусов и композиции поксвирусов | |
US10087423B2 (en) | Method for harvesting expression products | |
CN105012947B (zh) | 狂犬病病毒的纯化方法 | |
CN107567496A (zh) | 有关病毒的无菌纯化方法 | |
ES2733489T3 (es) | Proceso de purificación de poliovirus a partir de cultivos celulares | |
Grein et al. | Concepts for the production of viruses and viral vectors in cell cultures | |
RU2443779C2 (ru) | Способ получения препарата рекомбинантного аденовируса, характеризующегося сниженным коэффициентом соотношения физических и инфекционных вирусных частиц, и генно-терапевтический лекарственный препарат, полученный таким способом | |
US20200040063A1 (en) | Process of cloning and further purification to make a recombinant intravenous immunoglobulin | |
Ma et al. | Affinity chromatography for virus-like particle manufacturing: challenges, solutions, and perspectives | |
CN113913397A (zh) | 一种溶瘤病毒的纯化方法 | |
Cross et al. | Assays for the release of cellular gene therapy products | |
BELL et al. | Patent 2841831 Summary | |
Reece-Ford et al. | Aspects of process development for virus vector production to improve quality and quantity | |
Nanomicelles | CELL PROCESSING AND VECTOR MANUFACTURE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: American California Applicant after: Hilakin biological therapy Limited by Share Ltd Address before: American California Applicant before: Jennerex, Inc. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: JENNEREX BIOTHERAPEUTICS ULC TO: XILAJIN BIOLOGICAL TREATMENT CO., LTD. |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1194296 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: SILLAJEN INC. Free format text: FORMER OWNER: XILAJIN BIOLOGICAL TREATMENT CO., LTD. Effective date: 20150213 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150213 Address after: Busan Applicant after: Kirn David Address before: American California Applicant before: Hilakin biological therapy Limited by Share Ltd |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1194296 Country of ref document: HK |